Mr. Jonathan Robinson reports

VENTRIPOINT ISSUES OPTION GRANTS AND REPORTS EXERCISE OF OPTIONS

In January, 2023, Ventripoint Diagnostics Ltd. granted an aggregate of 1,115,000 options to directors, officers, employees, contractors and consultants of the corporation with an exercise price of 30 cents and with terms of 10 years and vesting from immediately to over three years. Of these option grants, 850,000 were awarded to directors and officers of the Corporation. In May 2023, the Corporation granted an aggregate of 500,000 options to a consultant of the Corporation with an exercise price of $0.20 and with terms of 2 (two) years and vests quarterly at 3, 6, 9 and12 months The Corporation now has 5,463,641 options available for future grants under the Stock Option Plan as approved by shareholders at the last Special and Annual General Meeting on August 16, 2022.

Since the last update (see NR January 21, 2022), a total of 1,005,000 options were exercised with a weighted average price of $0.30 per share for gross proceeds to the Corporation of $198,450. There are currently 10,218,750 option grants outstanding with exercise prices between $0.10 to $0.70 with a weighted average price of $0.28, and 6,983,333 of these options have vested.

The Corporation currently has 156,823,905 common shares issued and outstanding.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.